Clinical Trial Update: Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial in newly diagnosed multiple myeloma comparing cyclophosphamide, lenalidomide, and dexamethasone induction with autologous stem cell transplant aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Alkeran (melphalan)
• Cytoxan (cyclophosphamide)
• Decadron (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: Fondazione EMN Italy Onlus | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED